Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C40H67NO14 |
| Molecular Weight | 785.9583 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 16 / 16 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C
InChI
InChIKey=IEMDOFXTVAPVLX-YWQHLDGFSA-N
InChI=1S/C40H67NO14/c1-22(2)18-30(45)53-38-26(6)51-32(21-40(38,7)48)54-35-25(5)52-39(34(47)33(35)41(8)9)55-36-27(16-17-42)19-23(3)28(43)15-13-11-12-14-24(4)50-31(46)20-29(44)37(36)49-10/h11-13,15,17,22-29,32-39,43-44,47-48H,14,16,18-21H2,1-10H3/b12-11+,15-13+/t23-,24-,25-,26+,27+,28+,29-,32+,33-,34-,35-,36+,37+,38+,39+,40-/m1/s1
| Molecular Formula | C40H67NO14 |
| Molecular Weight | 785.9583 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 16 / 16 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.antimicrobe.org/drugpopup/josamycin.htmCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/mesh/68015570 | https://www.ncbi.nlm.nih.gov/pubmed/4012
Sources: http://www.antimicrobe.org/drugpopup/josamycin.htm
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/mesh/68015570 | https://www.ncbi.nlm.nih.gov/pubmed/4012
Josamycin is a macrolide antibiotic produced by Streptomyces narbonensis var. josamyceticus. Macrolides are inhibitors of protein synthesis. They impair the elongation cycle of the peptidyl chain by specifically binding to the 50S subunit of the ribosome. Josamycin has antimicrobial activity against a wide spectrum of pathogens. It is similar to erythromycin, but does not induce macrolide resistance in staphylococci and appears to have a lower incidence of gastrointestinal side effects. Josamycin is under investigation in US.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2363135 Sources: http://www.antimicrobe.org/drugpopup/josamycin.htm |
5.5 nM [Kd] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | Josamycin Approved UseBronchitis, Mediterranean spotted fever, Mycoplasma pneumonia. |
|||
| Curative | Josamycin Approved UseBronchitis, Mediterranean spotted fever, Mycoplasma pneumonia. |
|||
| Curative | Josamycin Approved UseBronchitis, Mediterranean spotted fever, Mycoplasma pneumonia. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Structure elucidation, complete NMR assignment and PM5 theoretical studies of new hydroxy-aminoalkyl-alpha,beta-unsaturated derivatives of the macrolide antibiotic josamycin. | 2010-04 |
|
| Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients. | 2001-11 |
|
| In vitro susceptibilities of rapidly growing mycobacteria to telithromycin (HMR 3647) and seven other antimicrobials. | 2000-01 |
|
| In vitro stimulation of polymorphonuclear cell adhesion by ribomunyl and antibiotic + ribomunyl combinations: effects on CD18, CD35 and CD16 expression. | 1993-02 |
|
| In vitro activity of antimicrobial agents against mycobacteria. | 1988 |
|
| Screening for new compounds with antiherpes activity. | 1984-10 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.antimicrobe.org/drugpopup/josamycin.htm
Bronchitis: 500 mg three times daily for up to 14 days.
Mediterranean spotted fever: 1 g every 8 hours for 5 days.
Mycoplasma pneumonia: 2 g per day (in four equally divided doses) for 7 days.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4012
The MIC values for josamycin were: 0.007-0.25 ug/ml (Mycoplasma pneumoniae), 0.007-0.25 ug/ml (Streptococcus pneumoniae), 0.06-0.5 ug/ml (Streptococcus pyogenes), 0.5-2.0 ug/ml (Staphylococcus aureus), 0.5-8.0 ug/ml (Haemophilus influenzae), 0.125->8 ug/ml (Bacteroides fiagilis).
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:26:52 GMT 2025
by
admin
on
Mon Mar 31 18:26:52 GMT 2025
|
| Record UNII |
YX09Z4QW5Y
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
m6775
Created by
admin on Mon Mar 31 18:26:52 GMT 2025 , Edited by admin on Mon Mar 31 18:26:52 GMT 2025
|
PRIMARY | Merck Index | ||
|
DTXSID501016463
Created by
admin on Mon Mar 31 18:26:52 GMT 2025 , Edited by admin on Mon Mar 31 18:26:52 GMT 2025
|
PRIMARY | |||
|
16846-34-7
Created by
admin on Mon Mar 31 18:26:52 GMT 2025 , Edited by admin on Mon Mar 31 18:26:52 GMT 2025
|
PRIMARY | |||
|
5282322
Created by
admin on Mon Mar 31 18:26:52 GMT 2025 , Edited by admin on Mon Mar 31 18:26:52 GMT 2025
|
PRIMARY | |||
|
YX09Z4QW5Y
Created by
admin on Mon Mar 31 18:26:52 GMT 2025 , Edited by admin on Mon Mar 31 18:26:52 GMT 2025
|
PRIMARY |